The Scottish Medicines Consortium (SMC) issues restricted recommendation for use of inotuzumab ozogamicin in the treatment of adults with relapsed/refractory acute lymphoblastic leukaemia (ALL) in Scotland.
Read more here: leukaemiacare.org.uk/suppor...
The decision from the SMC in recommending the use of inotuzumab ozogamicin for relapsed or refractory adult ALL patients is very welcome.
In August last year, NICE did not recommend the same drug for use in England. The decision was, however, successfully appealed and the HTA has now gone back to the committee for a second decision.
